I2U has created several case studies to identity and illuminate the discrete challenges preventing the value maximization of breakthrough medicines, and lessons learned for future innovations. To uncover these challenges, I2U conducted interviews with a wide range of system leaders and stakeholders, supported by extensive background research on implementation challenges and approaches across Canada and in a focused group of comparator jurisdictions.

Looking across these case studies, I2U identified 7 distinct implementation challenges each with the potential to diminish the optimal patient and system impact of a given breakthrough medicine: